Ocuphire Pharma Inc. (OCUP)
Ocuphire Pharma Statistics
Share Statistics
Ocuphire Pharma has 27.13M shares outstanding. The number of shares has increased by 4.64% in one year.
| Shares Outstanding | 27.13M |
| Shares Change (YoY) | 4.64% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 10.87% |
| Shares Floating | 24.52M |
| Failed to Deliver (FTD) Shares | 21.32K |
| FTD / Avg. Volume | 15.32% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -6.51 and the forward PE ratio is null. Ocuphire Pharma's PEG ratio is 0.04.
| PE Ratio | -6.51 |
| Forward PE | n/a |
| PS Ratio | 3.41 |
| Forward PS | null |
| PB Ratio | 1.3 |
| P/FCF Ratio | -58.44 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Ocuphire Pharma has an Enterprise Value (EV) of 14.48M.
| EV / Sales | 0.76 |
| EV / EBITDA | -1.45 |
| EV / EBIT | -13.03 |
| EV / FCF | -13.03 |
Financial Position
The company has a current ratio of 13.35, with a Debt / Equity ratio of 0.
| Current Ratio | 13.35 |
| Quick Ratio | 13.35 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -20.01% and Return on Invested Capital is -21.19%.
| Return on Equity | -20.01% |
| Return on Assets | -18.51% |
| Return on Invested Capital | -21.19% |
| Revenue Per Employee | $1.36M |
| Profits Per Employee | $-713.29K |
| Employee Count | 14 |
| Asset Turnover | 0.35 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 12K |
| Effective Tax Rate | -0.12% |
Stock Price Statistics
The stock price has increased by -22.52% in the last 52 weeks. The beta is 0.31, so Ocuphire Pharma's price volatility has been higher than the market average.
| Beta | 0.31 |
| 52-Week Price Change | -22.52% |
| 50-Day Moving Average | 1.23 |
| 200-Day Moving Average | 1.68 |
| Relative Strength Index (RSI) | 37.64 |
| Average Volume (20 Days) | 139.15K |
Income Statement
In the last 12 months, Ocuphire Pharma had revenue of 19.05M and earned -9.99M in profits. Earnings per share was -0.46.
| Revenue | 19.05M |
| Gross Profit | 19.04M |
| Operating Income | -10.56M |
| Net Income | -9.99M |
| EBITDA | -9.97M |
| EBIT | -9.97M |
| Earnings Per Share (EPS) | -0.46 |
Balance Sheet
The company has 50.5M in cash and 0 in debt, giving a net cash position of 50.5M.
| Cash & Cash Equivalents | 50.5M |
| Total Debt | 0 |
| Net Cash | 50.5M |
| Retained Earnings | -81.47M |
| Total Assets | 44.83M |
| Working Capital | 40.64M |
Cash Flow
In the last 12 months, operating cash flow was -1.11M and capital expenditures 0, giving a free cash flow of -1.11M.
| Operating Cash Flow | -1.11M |
| Capital Expenditures | 0 |
| Free Cash Flow | -1.11M |
| FCF Per Share | -0.05 |
Margins
Gross margin is 99.97%, with operating and profit margins of -55.45% and -52.42%.
| Gross Margin | 99.97% |
| Operating Margin | -55.45% |
| Pretax Margin | -52.36% |
| Profit Margin | -52.42% |
| EBITDA Margin | -52.33% |
| EBIT Margin | -55.45% |
| FCF Margin | -5.84% |
Dividends & Yields
OCUP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -15.37% |
| FCF Yield | -1.71% |
Analyst Forecast
The average price target for OCUP is $14, which is 1096.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $14 |
| Price Target Difference | 1096.6% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Nov 6, 2020. It was a backward split with a ratio of 1:4.
| Last Split Date | Nov 6, 2020 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | 1.92 |
| Piotroski F-Score | 2 |